Breast Cancer

乳腺癌计划是一项非常成功的多学科乳腺癌研究和治疗 该计划由来自15个部门的44名成员组成。该计划具有独特的优势，具有 发展为基础科学家之间的成功合作和共同目标，翻译 研究人员和临床医生促进临床和转化性研究。这项计划充分利用了： (1)我们在局部晚期乳腺癌(LABC)方面的专业知识，作为研究肿瘤转移和 免疫，以及电离辐射对正常和肿瘤组织的影响；(2)我们与 贝尔维尤医院中心，美国最大的公立医院集团的一部分；和(3)我们的 有与大量多种族、国际人口打交道的经验，这些人口主要由医疗人员组成 服务不足和患有乳腺癌的少数族裔妇女。 自2002年以来，该计划已经开发了五个资金充足的研究主题，重点是入侵， 转移和抗血管生成治疗、乳腺癌中的激素信号、放射生物学和抗肿瘤 免疫、激素信号和社会文化研究，以增加少数群体和 在临床试验中医疗服务不足的妇女。这个项目的成员已经发表了90多篇文章 合作发表研究论文，启动了许多研究人员发起的临床试验，积累了400多名患者 为了试验，增加了招募少数民族妇女进行临床试验，制定了资助的多民族/多文化 为增加少数族裔妇女在筛查和临床试验中的收益而开展的外展治疗方案； 获得了102.846.95亿美元的同行评审资金。 有四个重要的临床项目是大部分协作翻译的基础。 乳腺癌计划的临床研究平台：(1)激素信号在调节肿瘤生长中的作用 乳腺癌的发生和发展；(2)对局部晚期乳腺癌的遗传学和分子理解 乳腺癌，一种长期研究不足的乳腺癌形式，在医疗服务不足的人群中很常见 和全球领先的乳腺癌报告；(3)开发新的治疗方法和用途 乳腺癌的放射治疗；辐射诱导纤维化的生物学理解；以及分子 了解不同辐射对正常和乳腺肿瘤组织的影响；以及(4)抗肿瘤的诱导 通过局部辐射有针对性地控制免疫反应而产生的免疫力。 供资总额从4 045 436美元增加到11 928 611美元。会员人数从34人增加到44人。 过去五年的出版物总数包括300份，其中13%是方案内出版物，16%是方案间出版物。

The Breast Cancer Program is a highly successful multidisciplinary breast cancer research and treatment program composed of 44 members from 15 Departments. This program has unique strengths which have developed into successful collaborations and common goals among basic scientists, translational researchers and clinicians to promote clinical and translational research. This program has capitalized on: (1) Our expertise in locally advanced breast cancer (LABC) as a platform to study tumor metastasis and immunity, and the effects of ionizing radiation on normal and tumor tissue; (2) Our unique relationship with Bellevue Hospital Center, part of the largest public hospital group in the United States; and (3) Our experience in working with large multi-ethnic, international populations comprised of largely medically underserved and minority women with breast cancer. Since 2002, this program has developed five well funded research themes focused on invasion, metastasis and anti-angiogenic therapy, hormonal signaling in breast cancer, radiation biology and antitumor immunity, hormonal signaling, and socio-cultural research to increase participation of minority and medically underserved women in clinical trials. The members of this program have published over 90 research papers collaboratively, opened many investigator initiated clinical trials, accrued over 400 patients to trial, increased recruitment of minority women to clinical trial, developed a funded multi-ethnic/multicultural outreach-inreach program to increase accrual of minority women into screening and clinical trials, and secured $10,284,695 million dollars in peer-reviewed funding. There are four important clinical programs that are the basis for much of the collaborative translational- . clinical research platforms of the breast cancer program: (1) Role of hormonal signaling in the regulation of breast cancer development and progression; (2) A genetic and molecular understanding of locally advanced breast cancer, a persistently under-studied form of breast cancer common among the medically underserved and a leading presentation of breast cancer worldwide; (3) Development of new approaches and uses for radiation treatment in breast cancer; biological understanding of radiation-induced fibrosis; and molecular understanding of differential radiation effects on normal and breast tumor tissues; and (4) Induction of antitumor immunity through targeted control of the immune response by local radiation. Total funding has increased from $4,045,436 to $11,928,611. Membership has incresed from 34 to 44. Total publications for the past five years include 300 of which 13% are intra-programmatic and 16% are interprogrammatic.